Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06457503 · ClinicalTrials.gov registry record · Phase 4
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
A Phase 4 study of Nasopharyngeal Cancer Recurrent, sponsored by Coherus Oncology.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 13
- Study locations
NCT06457503: Recruiting Phase 4 study of Nasopharyngeal Cancer Recurrent, sponsored by Coherus Oncology.
NCT06457503 is a Phase 4 study of Nasopharyngeal Cancer Recurrent that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06457503, a Phase 4 study of Nasopharyngeal Cancer Recurrent, is actively recruiting participants, sponsored by Coherus Oncology.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Toripalimab
Study Locations (13)
California
- University of California, Irvine - Irvine
- University of California, San Francisco - San Francisco
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Cancer Center - Detroit
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Georgia
- Emory Winship Cancer Institute - Atlanta
Massachusetts
- Boston Medical Center - Boston
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
What NCT06457503 shows while recruiting
NCT06457503 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Nasopharyngeal Cancer Recurrent appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT06457503 lists 13 locations in 10 states (California, Michigan, Ohio).
Frequently Asked Questions
What is clinical trial NCT06457503 about?
NCT06457503 is a clinical study titled "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer". This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
What is the current status of trial NCT06457503?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-11-01. Estimated completion is 2027-12.
What conditions does trial NCT06457503 study?
This clinical trial studies the following conditions: Nasopharyngeal Cancer Recurrent.
What interventions are being tested in trial NCT06457503?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT06457503?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06457503 being conducted?
This trial has 13 study locations across Arkansas, California, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06457503's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI